Ein Blick sollte sich lohnen

stelle mal nach meiner Meinung einen sehr interessanten Wert vor der gestern 2 News rausbrachte und unter hohem Volumen in der Spitze fast die 0,06$ erreichte.
Heutiger Rücksetzer unter sehr geringem Volumen fast bis auf die Unterstüzung von 0,02$ gefallen - aktueller Kurs 0,0235$

Chart:

Quelle:  http://ih.advfn.com/p.php?pid=nmona&article=46237083

Manhattan Pharmaceuticals Achieves Ariston Merger Milestone
Datum : 31/01/2011 @ 18h11
Quelle : GlobeNewswire Inc.
Name : Manhattan Pharmaceuticals, Inc. (MHAN)
Kurs :  0.0235  -0.0065 (-21.67%) @ 19h20

 
Manhattan Pharmaceuticals Achieves Ariston Merger Milestone

Manhattan Pharma (OTCBB:MHAN)
Intraday Stock Chart
Heute : Tuesday 1 February 2011

Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that the company's Board of Directors has decided to continue development of AST-915, an orally delivered treatment for essential tremor. This decision was made following the announcement of favorable clinical results from a Phase 1/2 clinical study of AST-915 conducted by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) under a CRADA agreement between the NIH and Ariston Pharmaceuticals, Inc., a wholly owned subsidiary of Manhattan Pharmaceuticals, Inc. Data from this study, previously announced on December 16, 2010, demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power. The company intends to continue to work with the NIH and to proceed toward Phase 2 with the AST-915 development program.

Under the terms of the merger agreement between Manhattan Pharmaceuticals, Inc. and Ariston Pharmaceuticals, Inc., the achievement of this milestone requires the company to issue 8,828,029 shares of its common stock to debt holders and former shareholders of Ariston.

About Essential Tremor

Essential tremor is a common movement disorder that is characterized by involuntary shaking of the hands, arms, head, voice and upper body. The most disabling tremors occur during voluntary movement affecting common skills such as writing, eating and drinking and body care. According to the International Essential Tremor Foundation, an estimated 10 million Americans have essential tremor. The condition is most common among people over 60, but it also occurs in children, adolescents and the middle-aged. There is no curative treatment for essential tremor and current therapy is inadequately effective in a large portion of patients and/or limited by side effects. Manhattan Pharmaceuticals owns worldwide rights to AST-915 and believes it may provide a new treatment option for this serious and prevalent disorder.

About Manhattan Pharmaceuticals, Inc.

Manhattan Pharmaceuticals, Inc. is a specialty healthcare product company focused on the development and commercialization of innovative treatments for underserved patient populations. The company is currently focused on two programs: AST-726, a nasally delivered vitamin B12 remediation treatment, and AST-915, an orally delivered product candidate for the treatment of essential tremor. The company also has an equity ownership position in Hedrin®, a non-insecticide treatment for head lice currently being developed by Nordic Biotech for the North American market.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Manhattan Pharmaceuticals, Inc.'s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "intends," "anticipates," "expects," "plans," "believes," "intends," "will," and similar words or phrases. These statements are based on Manhattan Pharmaceuticals, Inc.'s current expectations, forecasts and assumptions, which are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, that any clinical study will be completed or will return positive results. Other risks that may affect forward-looking information contained in this press release include the company's extremely limited capital resources, the risk that the results of clinical trials may not support the company's or its joint venture's claims, the risk that the company's product candidates may not achieve market acceptance in North America or elsewhere, the company's reliance on third-party researchers to develop its product candidates, the risk that sufficient capital may not be available to develop and commercialize the company's product candidates or permit the company's continuing business operations, the risk that $1,315,000 of aggregate principal amount of the company's outstanding indebtedness is now past due and to date the lenders thereof have not waived events of default or extended the maturity date of such indebtedness, the risk that any financing transaction or restructuring of indebtedness that the company may pursue would likely result in substantial dilution to the company's equityholders, and the company's lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2009. Manhattan Pharmaceuticals, Inc. assumes no obligation to update these statements, whether as a result of new information, future events, or otherwise, except as required by law.

CONTACT: Manhattan Pharmaceuticals, Inc.
        Michelle Y. Carroll, Vice President, Corporate Development
        (212) 582-3950

Quelle: http://ih.advfn.com/p.php?pid=nmona&article=46238753

- Current report filing (8-K)
Datum : 31/01/2011 @ 19h57
Quelle : Edgar (US Regulatory)
Name : (MHAN)
Kurs :  0.0235  -0.0065 (-21.67%) @ 19h20

 
- Current report filing (8-K)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K


CURRENT REPORT


PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934




Date of Report (Date of earliest event reported): January 31, 2011




Manhattan Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware     001-32639     36-3898269  
(State or other jurisdiction
of incorporation)     (Commission File Number)     (IRS Employer
Identification No.)  



48 Wall Street, Suite 1110
New York, New York 10005
(Address of principal executive offices) (Zip Code)


(212) 582-3950
(Registrant's telephone number, including area code)




Not applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  



 
1
--------------------------------------------------

 


Item 8.01   Other Events  

 
On January 31, 2011 Manhattan Pharmaceuticals, Inc. announced that its company’s Board of Directors has decided to continue development of AST-915, an orally delivered treatment for essential tremor. Under the terms of the merger agreement between Manhattan Pharmaceuticals, Inc. and Ariston Pharmaceuticals, Inc., the achievement of this milestone requires the company to issue 8,828,029 shares of its common stock to debt holders and former shareholders of Ariston.
 
Item 9.01   Financial Statements and Exhibits  

                     
(d)  Exhibits  
     
Exhibit No.  Description  
99.1    Press release dated January 31, 2011.  







SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

Quelle:http://investorshub.advfn.com/boards/read_msg.aspx?message_id=59366713

ImTC     Share   Monday, January 31, 2011 1:53:08 PM  
Re: None     Post #  of 348  

New investors read post #328 from Ecomike http://ir.manhattanpharma.com/secfiling.cfm?filingid=1144204-11-3638

We have an SEC report filing, update.

Also I had a chat (several) with Carroll at MHAN recently. The prior SEC reports were confusing to me and others. Seems Nordic biotech NEVER has owned any MHAN shares, and does not currently own any shares, and the puts and warrants owned by Nordic are all cancelled now, so the fear of a 200% increase in shares at the hand of Nordic or dead!!!!!! Also, Carroll tells me the market for the current lead B-12 product is far larger and easier to tap than the Hedrin was going to be! Like $100,000,000 per year market potential! And far easier to market.

bezahlt sind 0,025$ - aktueller Kurs

BID                                    ASK

2MM bei 0,025$                1MM bei 0,029$
1MM bei 0,0225$              1MM bei 0,0299$
1MM bei 0,02$                  1MM bei 0,03$ danach 0,045$

Rückblende:

nach den letzten News vom 31.01.2011 wurden die meisten Aktien bei 0,04$ und mehr gekauft ( über 1,5 Millionen Tagesumsatz), gestern mit 150.000 Stück auf 0,0225$ runtergezogen. Mein erstes Kursziel bei steigendem Volumen mind. 0,04$

Webseite umbedingt anschauen:  http://www.manhattanpharma.com/

Hummel

Wäre schon eine bahnbrechende Sache.Allerdings  ist es bis zur Zulassung noch ein weiter Weg. AST-915 befindet sich momentan in Phase 2.
Für diejenigen die sich nicht auskennen bis zur Zulassung durchläuft ein Medikament
im Regelfall  Phase 1  bis 3   .jede Phase dauert ca 2 Jahre,wurden alle Tests positiv durchlaufen kann das Pharma Unternehmen die Zulassung  des Medikaments beantragen.Sollte dies hier geschen ,wäre hier enormes Potential vorhanden .Den es gibt momentan kein vergleichbares Medikament  zur Behandlung von Bewegungstörungen.
Wenn man dann noch berücksichtigt Welche Medikamente sich noch in der Pipline befinden ,und welches Markt potenzial vorhanden ist ,na dann kann sich jeder ein Bild machen.
Werde mal versuchen im Bereich von0,020bis 0,030 einige Stücke einzusammeln.Mal sehen wo die Reise hin geht.
keine empfehlung zu irgend etwas  

in Berlin sehr gering ,sollte direkt an der nasdaq Otc gehandelt werden.  

vielen Dank für den Beitrag.
Meine Spekulation ist eher eine Übernahme vor einer Marktreife oder die Spekulation das es passieren könnte ( das reicht ja meistens schon aus).
Aktuelle Marktkap. gerade einmal 3 Millionen US$ - da könnte schnell mal das 10-fache bei rauskommen.

lg,

Hummel

Das ist mir schon klar ,wurde von Dir ja bereits oben beschrieben ,habs zumindest so verstanden. Jedoch bietet das Invest auch mittelfristig sehr sehr hohes Potenzial  selbst dann wenn deine Spekulation nicht aufgeht wäre dies immer noch ein sehr aussichtsreicher Wert.Denke auch das hier eventuell eine Übernahme ansteht.Wollte  mit Beitrag 6 auch nur klar machen welches Potential in dieser Firma steckt.

ps deine Investstrategie ist mir bekannt ,wäre schön wenn sie eintrifft.
Mfg  

bewegung in  unser Invest.Denke wir werden hier noch viel Freude haben .Potenzial ist enorm.Ist halt noch unentdeckt .Aber wenn da Volumen rein kommt ,na dann???  

sich momentan ständig zwischen 0,0185 und 0,0240 .Mit einem engen Stopp bei 0,0165
kann man hier nicht viel falsch machen, der Rest ist nur eine Frage der Zeit.Allen investierten viel Erfolg.An den fundamentalen Daten hat sich nichts verändert

Ps keine Empfehlung zu irgend was ,jeder handelt auf eigenes Risiko